 Anebulo Pharmaceuticals Inc NASDAQ: ANEB has announced topline data from Part A of an ongoing Phase 2 trial of ANEB-001 to treat acute cannabinoid intoxication ACI. Part A was a 60-subject trial designed to evaluate the effectiveness of a single dose of ANEB-001 in healthy. 